spacer
home > ebr > winter 2003 > editor's letter
PUBLICATIONS
European Biopharmaceutical Review

Editor's Letter

As we round up 2003, the European biotechnology sector looks ahead to 2004 with somewhat more optimism than it faced entering 2003. This appears to be the message in the marketplace, permeating numerous conference floors and news stories in recent weeks - not least the grand finale, the inaugural CORDIA-EuropaBio Convention, held in Vienna in December 2003 and reviewed later in this issue.

Whilst recent figures from Ernst & Young on European venture investment cite a decline in activity between Q2 and Q3 this year, the UK is highlighted as the exception to this negative picture potentially marking an upturn across Europe with an increase of 52 per cent


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Senior Consultant at Technomark Consulting Services
spacer
Dr Helen Abbott
spacer
spacer
spacer
Amy Curtis
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sense Accelerates Instrument-Free Molecular Diagnostic Test for COVID-19

April 1, 2020 – Sense Biodetection Limited (Sense) has today announced an accelerated programme to launch the world’s first instrument-free, point-of-care molecular diagnostic test for SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement